May 21st, 2014
2013 Blavatnik Fellows Share Lessons in Life Science Entrepreneurship
On May 21, the inaugural group of Blavatnik Fellows shared their experiences, project progress, and the first year of the program.
News
Press Contact: Kirsten Mabry | (617) 495-4157
Featured Tags:
May 21st, 2014
On May 21, the inaugural group of Blavatnik Fellows shared their experiences, project progress, and the first year of the program.
October 18th, 2013
On October 17, OTD and HBS kicked-off the new fellowship program with a reception to welcome the inaugural fellows.
July 15th, 2013
Paris (France), 15 July 2013 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it
has initiated a research and development collaboration on novel engineered botulinum toxins
with Harvard Medical School (Harvard).
Under the terms of the agreement, Ipsen will fund Harvard research for at least three years
with the aim to discover, evaluate and develop novel engineered recombinant botulinum
toxins for the treatment of serious neurologic diseases.
May 16th, 2013
Target PGB (PEPTIDOGLYCAN BIOSYNTHESIS) is the focus of collaboration designed to develop novel family of antibacterial drugs based on highly validated target
April 29th, 2013
Harvard Gazette: Blavatnik Biomedical Accelerator a catalyst to transform early-stage research.